AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00633685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
Study NCT00633685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
Study NCT00906763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chocolate
Description: A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
Study NCT01524406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP593
Description: Oral, twice a day.
Study NCT01524406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice a day.
Study NCT04707508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg and metformin
Description: Valsartan 80 mg once daily in addition to metformin monotherapy
Study NCT04707508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin monotherapy
Study NCT01259596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
Study NCT01259596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nondirective supportive therapy
Description: weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
Study NCT00242320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
Study NCT00242320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast
Description: to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
Study NCT00242320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04526431 — intervention group
Intervention type: DRUG
Intervention: Dosage Forms Oral
Description: Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
Study NCT03489317 — intervention group
Intervention type: DRUG
Intervention: Simvastatin 10mg
Description: Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study NCT03489317 — intervention group
Intervention type: DRUG
Intervention: Amlodipine 5mg
Description: Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study NCT04524832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
Study NCT00202969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
Study NCT00202969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 plus CDDP
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
Study NCT00202969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU plus CDDP
Description: 5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
Study NCT03920371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gamma camera imaging
Description: Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
Study NCT02276820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viralym-A
Description: Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
Study NCT01604447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia prevention with plastic bag
Description: Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
Study NCT01604447 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hypothermia prevention without plastic bag
Description: Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
Study NCT00804206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravitreal bevacizumab before panretinal photocoagulation
Study NCT00804206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravitreal Bevacizumab after panretinal photocoagulation
Study NCT01933919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate
Description: Film-coated tablet containing 25 mg of fluvoxamine maleate
Study NCT01933919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvoxamine maleate
Description: Film-coated tablet containing 25 mg of fluvoxamine maleate
Study NCT01933919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching to fluvoxamine maleate
Study NCT03788135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cooling
Description: the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
Study NCT02591563 — intervention group
Intervention type: OTHER
Intervention: procedures
Description: Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
Study NCT03747653 — intervention group
Intervention type: DRUG
Intervention: ADVATE
Description: Patients will be administered a single dose of ADVATE.
Study NCT03747653 — intervention group
Intervention type: DRUG
Intervention: FRSW107
Description: Patients will be administered a single dose of FRSW107 for Injection.
Study NCT02361723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-290
Study NCT04374305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Oral daily per predetermined dosage per protocol.
Study NCT04374305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Oral daily per predetermined dosage per protocol.
Study NCT03894527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Bout of Exercise
Description: An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
Study NCT03894527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
Study NCT04656912 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperbaric oxygen therapy
Description: Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
Study NCT01005108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
Study NCT03220009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT03220009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT03220009 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT01188382 — intervention group
Intervention type: PROCEDURE
Intervention: CSF dynamic investigation
Study NCT03587558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
Study NCT03220009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03220009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03220009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03587558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide
Description: Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
Study NCT00704743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical cast
Description: Arm cast/immobilization technique for wrist fracture
Study NCT00704743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified sugar tong cast
Description: Arm cast/immobilization technique for wrist fracture
Study NCT00704743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar dorsal splint
Description: Arm cast/immobilization technique for wrist fracture
Study NCT04398017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal echography
Description: Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
Study NCT04398017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echography
Description: Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
Study NCT03220009 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT03072017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT
Description: Breathing-based intervention
Study NCT04346628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
Study NCT04346628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match favipiravir administered orally through day 10.
Study NCT04346628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Standard of care treatment for COVID-19 infection
Study NCT04346628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Standard of care treatment for COVID-19 infection
Study NCT03220009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03220009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo active surveillance
Study NCT03220009 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03220009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03503409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: 500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
Study NCT04362735 — intervention group
Intervention type: DRUG
Intervention: Vedolizumab
Description: Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.
Study NCT01741129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP (SLE)
Description: PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
Study NCT01741129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal IMV (SLE)
Description: PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with epinephrine
Description: bupivacaine 0.5% with epinephrine 30cc
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Description: bupivacaine 0.5% with epinephrine 30cc
Study NCT03094663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 40 mg/ml, 1 ml
Study NCT03188315 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HPV oncogenes
Description: PCR and oncogenes detection
Study NCT03188315 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HPV oncogenes
Description: PCR and oncogenes detection
Study NCT01447433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
Study NCT01447433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy restriction
Description: A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
Study NCT01447433 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Energy restriction
Description: A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
Study NCT02831452 — intervention group
Intervention type: OTHER
Intervention: pelvic floor muscle strength evaluation
Study NCT03638947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swab and decolonization using povidone-iodine cleansing
Description: Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
Study NCT02836990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena Incision Management System
Description: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
Study NCT02836990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Description: A surgical skin adhesive used to prevent surgical wound infections
Study NCT00891592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells
Description: Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~* 1xE5 cells/kg~* 2xE6 cells/kg~* 3xE7 cells/kg~* 4xE8 cells/kg
Study NCT01213836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel XR- quetiapine fumarate extended release
Description: Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
Study NCT01213836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel IR - quetiapine fumarate
Description: Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
Study NCT00891592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Arm
Description: Single infusion of Cord Blood Cells
Study NCT03185871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
Study NCT02653872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7986
Description: Oral solution, single dose, dilution from concentrate
Study NCT01477190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Description: isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
Study NCT01477190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Control Analgesia (PCA) Morphine
Description: PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
Study NCT01327040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light exposure
Description: 12-hour light exposure of approximately 200 lux
Study NCT01982604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-Inhalation Powder A
Description: Inhaled Insulin
Study NCT01982604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-Inhalation Powder B
Description: Inhaled Insulin
Study NCT01850784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High energy formula
Description: The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
Study NCT01850784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Description: The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
Study NCT03738566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal self-dilation therapy
Description: Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
Study NCT03738566 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Esophageal self-dilation therapy
Description: Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
Study NCT03738566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal self-dilation therapy
Description: Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
Study NCT03738566 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic therapy with esophageal dilation
Description: A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
Study NCT03738566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy with esophageal dilation
Description: A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
Study NCT03738566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy with esophageal dilation
Description: A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.